ArticleAnalytical chemistry2020
Dose-Response Metabolomics To Understand Biochemical Mechanisms and Off-Target Drug Effects with the TOXcms Software.
Article in Analytical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Using MetaboAnalyst 6.0 for exposomics data analysis-from LC-MS2 spectra processing to dose-response modeling and causal inference.Nature protocols · 2026Review
- Transient exposure to bisphenol F in early life affects the metabolic health of adults.Exposome · 2026Article
- Metabolomics Spectral Processing, Data Analysis, and Multiomics Integration Using MetaboAnalyst 6.0.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Unintended VOC emissions from cotton and viscose pads complicate olfactory experiments.Scientific reports · 2025Article
- Developmental exposure of zebrafish to 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) elicits MPTP-like neurotoxicity.Neurotoxicology · 2025Article
- Harnessing Metabolomics to Advance Nutrition-Based Therapeutics for Inflammation: A Systematic Review of Randomized Clinical Trials.Metabolites · 2025Review
- Ion suppression correction and normalization for non-targeted metabolomics.Nature communications · 2025Article
- Natural product virtual-interact-phenotypic target characterization: A novel approach demonstrated with Salvia miltiorrhiza extract.Journal of pharmaceutical analysis · 2025Article
- Review
- MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation.Nucleic acids research · 2024Article
- Cytosolic and mitochondrial NADPH fluxes are independently regulated.Nature chemical biology · 2023Article
- Uncoupled glycerol-3-phosphate shuttle in kidney cancer reveals that cytosolic GPD is essential to support lipid synthesis.Molecular cell · 2023Article
- Editorial: Double-edged swords: Important factors connecting metabolic disorders and cancer development - from basic research to translational applications.Frontiers in endocrinology · 2023Article
- Integrated dose-response metabolomics with therapeutic effects and adverse reactions may demystify the dosage of traditional Chinese medicine.Chinese medicine · 2022Article
- A multidimensional metabolomics workflow to image biodistribution and evaluate pharmacodynamics in adult zebrafish.Disease models & mechanisms · 2022Article
- Targeting fatty acid β-oxidation impairs monocyte differentiation and prolongs heart allograft survival.JCI insight · 2022Article
- Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia.Scientific reports · 2021Article
- Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia.iScience · 2021Article
- A Practical Guide to Metabolomics Software Development.Analytical chemistry · 2021Article
- Deciphering the mechanism of action of antitubercular compounds with metabolomics.Computational and structural biotechnology journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Small-molecule drugs and toxicants commonly interact with more than a single protein target, each of which may have unique effects on cellular phenotype. Although untargeted metabolomics is often applied to understand the mode of action of these chemicals, simple pairwise comparisons of treated and untreated samples are insufficient to resolve the effects of disrupting two or more independent protein targets. Here, we introduce a workflow for dose-response metabolomics to evaluate chemicals that potentially affect multiple proteins with different potencies. Our approach relies on treating samples with various concentrations of compound prior to analysis with mass spectrometry-based metabolomics. Data are then processed with software we developed called TOXcms, which statistically evaluates dose-response trends for each metabolomic signal according to user-defined tolerances and subsequently groups those that follow the same pattern. Although TOXcms was built upon the XCMS framework, it is compatible with any metabolomic data-processing software. Additionally, to enable correlation of dose responses beyond those that can be measured by metabolomics, TOXcms also accepts data from respirometry, cell death assays, other omic platforms, etc. In this work, we primarily focus on applying dose-response metabolomics to find off-target effects of drugs. Using metformin and etomoxir as examples, we demonstrate that each group of dose-response patterns identified by TOXcms signifies a metabolic response to a different protein target with a unique drug binding affinity. TOXcms is freely available on our laboratory website at http://pattilab.wustl.edu/software/toxcms .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.